Literature DB >> 34020866

Successful orthotopic heart transplantation in CPTII deficiency.

Georgianne L Arnold1, Jessie Yester2, Elizabeth McCracken2, Brian D Feingold2, Jerry Vockley2.   

Abstract

Carnitine palmitoyl transferase II (CPT II) catalyzes the release of activated long-chain fatty acids from acylcarnitines into mitochondria for subsequent fatty acid oxidation. Depending on residual enzyme activity, deficiency of this enzyme leads to a spectrum of symptoms from early onset hypoglycemia, hyperammonemia, cardiomyopathy and death to onset of recurrent rhabdomyolysis in adolescents and young adults. We present a case of successful orthotopic heart transplantation in a patient with severe infantile onset cardiomyopathy due to CPT II deficiency identified through newborn screening. Excellent cardiac function is preserved 12 years post-transplantation; however, the patient has developed intermittent episodes of hyperammonemia and rhabdomyolysis later in childhood and early adolescence readily resolved with intravenous glucose. Successful heart transplant in this patient demonstrates the feasibility of this management option in patients with even severe forms of long chain fatty acid oxidation disorders.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  CPT2 deficiency; Cardiomyopathy; Carnitine palmitoyl transferase deficiency; Fatty acid oxidation disorder; Heart transplantation

Mesh:

Substances:

Year:  2021        PMID: 34020866      PMCID: PMC8899800          DOI: 10.1016/j.ymgme.2021.04.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  14 in total

1.  Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency.

Authors:  Laure Thuillier; Hidayeth Rostane; Veronique Droin; France Demaugre; Michèle Brivet; Noman Kadhom; Carina Prip-Buus; Stéphanie Gobin; Jean-Marie Saudubray; Jean-Paul Bonnefont
Journal:  Hum Mutat       Date:  2003-05       Impact factor: 4.878

2.  Biochemical and molecular correlations in carnitine palmitoyltransferase II deficiency.

Authors:  G D Vladutiu
Journal:  Muscle Nerve       Date:  1999-07       Impact factor: 3.217

3.  Mitochondrial Trifunctional Protein Deficiency: Severe Cardiomyopathy and Cardiac Transplantation.

Authors:  C Bursle; R Weintraub; C Ward; R Justo; J Cardinal; D Coman
Journal:  JIMD Rep       Date:  2017-11-10

Review 4.  Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential.

Authors:  Charles R Roe; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

5.  Disorders of creatine transport and metabolism.

Authors:  Nicola Longo; Orly Ardon; Rena Vanzo; Elizabeth Schwartz; Marzia Pasquali
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-02-09       Impact factor: 3.908

Review 6.  Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects.

Authors:  Jean-Paul Bonnefont; Fatima Djouadi; Carina Prip-Buus; Stephanie Gobin; Arnold Munnich; Jean Bastin
Journal:  Mol Aspects Med       Date:  2004 Oct-Dec

Review 7.  An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.

Authors:  Xavier Palomer; Laia Salvadó; Emma Barroso; Manuel Vázquez-Carrera
Journal:  Int J Cardiol       Date:  2013-08-06       Impact factor: 4.164

8.  Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.

Authors:  Charles R Roe; Henri Brunengraber
Journal:  Mol Genet Metab       Date:  2015-10-24       Impact factor: 4.797

9.  CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency.

Authors:  Paul J Isackson; Michael J Bennett; Uta Lichter-Konecki; Mary Willis; William L Nyhan; V Reid Sutton; Ingrid Tein; Georgirene D Vladutiu
Journal:  Mol Genet Metab       Date:  2008-06-11       Impact factor: 4.797

10.  Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates.

Authors:  Suzan J G Knottnerus; Isabella Mengarelli; Rob C I Wüst; Antonius Baartscheer; Jeannette C Bleeker; Ruben Coronel; Sacha Ferdinandusse; Kaomei Guan; Lodewijk IJlst; Wener Li; Xiaojing Luo; Vincent M Portero; Ying Ulbricht; Gepke Visser; Ronald J A Wanders; Frits A Wijburg; Arie O Verkerk; Riekelt H Houtkooper; Connie R Bezzina
Journal:  Int J Mol Sci       Date:  2020-04-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.